Current Hepatology Reports

, Volume 17, Issue 4, pp 485–491 | Cite as

Prevention and Management of HBV Infection in Patients with Chronic Kidney Disease Requiring Renal Transplantation

  • Andres F. CarrionEmail author
  • Paul Martin
Hepatitis B (J Lim, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Hepatitis B


Purpose of the Review

This review addresses clinical challenges of hepatitis B virus (HBV) infection in patients with chronic kidney disease and renal transplant recipients.

Recent Findings

Prophylactic antiviral therapy with nucleos(t)ide analogues is key to prevent HBV reactivation in renal transplant recipients. In addition, attaining adequate immunity following vaccination against HBV may permit transplantation of renal grafts from donors with evidence of prior HBV infection. The role of nucleos(t)ide analogues for treatment of recurrent or de novo HBV infection in renal transplant recipients is well established and preliminary experience demonstrate significant reductions in the median time in the renal transplant waiting list by transplanting HBsAg-positive renal grafts into HBsAg-positive recipients, without sacrificing graft or patient survival with the use of these agents.


Availability of potent nucleos(t)ide analogues results in improved outcomes following renal transplantation in patients with chronic HBV infection by avoiding recurrent or de novo infection.


Hepatitis B Chronic kidney disease Dialysis Renal transplantation Immunosuppression 


Compliance with Ethical Standards

Conflicts of Interest

Andres F. Carrion reports personal fees from Gilead, personal fees from BMS, during the conduct of the study. Paul Martin reports grants and personal fees from Gilead, grants and personal fees from BMS, during the conduct of the study.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–9.CrossRefGoogle Scholar
  2. 2.
    Fabrizi F, Martin P. Hepatitis B virus infection in dialysis patients. Am J Nephrol. 2000;20(1):1–11.CrossRefGoogle Scholar
  3. 3.
    Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–55.CrossRefGoogle Scholar
  4. 4.
    Garcia Agudo R, Aoufi Rabih S, Barril Cuadrado G, et al. Spanish multicentre PIBHE study: prevalence and immunization of chronic hepatitis B in haemodialysis patients in Spain. Nefrologia. 2016;36(2):126–32.CrossRefGoogle Scholar
  5. 5.
    Burdick RA, Bragg-Gresham JL, Woods JD, Hedderwick SA, Kurokawa K, Combe C, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2003;63(6):2222–9.CrossRefGoogle Scholar
  6. 6.
    Johnson DW, Dent H, Yao Q, Tranaeus A, Huang CC, Han DS, et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant. 2009;24(5):1598–603.CrossRefGoogle Scholar
  7. 7.
    Fabrizi F, Martin P, Messa P. Hepatitis B and hepatitis C virus and chronic kidney disease. Acta Gastro-Enterol Belg. 2010;73(4):465–71.Google Scholar
  8. 8.
    Tseng GY, Lin HJ, Fang CT, Cheng YT, Huang CH, Tseng GC, et al. Hemodialysis reduces the viral load in uremic patients with chronic hepatitis B infection. Ren Fail. 2008;30(10):1000–5.CrossRefGoogle Scholar
  9. 9.
    Martin P, Friedman LS. Chronic viral hepatitis and the management of chronic renal failure. Kidney Int. 1995;47(5):1231–41.CrossRefGoogle Scholar
  10. 10.
    Fabrizi F, Martin P, Messa P. Novel perspectives on the hepatitis B virus vaccine in the chronic kidney disease population. Int J Artif Organs. 2015;38(12):625–31.CrossRefGoogle Scholar
  11. 11.
    Ow MM, de Zoysa JR, Gane EJ. The impact of oral antiviral therapy on long-term survival of hepatitis B surface antigen-positive patients on haemodialysis. N Z Med J. 2014;127(1396):34–42.PubMedGoogle Scholar
  12. 12.
    Degos F, Lugassy C, Degott C, Debure A, Carnot F, Thiers V, et al. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. A prospective study of 90 patients. Gastroenterology. 1988;94(1):151–6.CrossRefGoogle Scholar
  13. 13.
    Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2005;5(12):2913–21.CrossRefGoogle Scholar
  14. 14.
    Reddy PN, Sampaio MS, Kuo HT, Martin P, Bunnapradist S. Impact of pre-existing hepatitis B infection on the outcomes of kidney transplant recipients in the United States. Clin J Am Soc Nephrol. 2011;6(6):1481–7.CrossRefGoogle Scholar
  15. 15.
    Rangel MC, Coronado VG, Euler GL, et al. Vaccine recommendations for patients on chronic dialysis. The advisory committee on immunization practices and the American Academy of Pediatrics. Semin Dial. 2000;13(2):101–7.CrossRefGoogle Scholar
  16. 16.
    Janssen JM, Heyward WL, Martin JT, Janssen RS. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus. Vaccine. 2015;33(7):833–7.CrossRefGoogle Scholar
  17. 17.
    • Zitt E, Hafner-Giessauf H, Wimmer B, et al. Response to active hepatitis B vaccination and mortality in incident dialysis patients. Vaccine. 2017;35(5):814–20 Retrospective cohort study suggesting signifcant recuction in all cause mortality associated with HBV vaccination of patients with CKD undergoing dialysis. CrossRefGoogle Scholar
  18. 18.
    He WY, Jin YJ, Wang WP, Li CL, Ji ZB, Yang C. Tissue elasticity quantification by acoustic radiation force impulse for the assessment of renal allograft function. Ultrasound Med Biol. 2014;40(2):322–9.CrossRefGoogle Scholar
  19. 19.
    Udell JA, Wang CS, Tinmouth J, FitzGerald JM, Ayas NT, Simel DL, et al. Does this patient with liver disease have cirrhosis? Jama. 2012;307(8):832–42.CrossRefGoogle Scholar
  20. 20.
    Varaut A, Fontaine H, Serpaggi J, Verkarre V, Vallet-Pichard A, Nalpas B, et al. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus. Transplantation. 2005;80(11):1550–5.CrossRefGoogle Scholar
  21. 21.
    Chopra A, Cantarovich M, Bain VG. Simultaneous liver and kidney transplants: optimizing use of this double resource. Transplantation. 2011;91(12):1305–9.CrossRefGoogle Scholar
  22. 22.
    • European Association For The Study Of The L. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85 European guidelines for diagnosis and management of HBV infection in the general population and special populations.CrossRefGoogle Scholar
  23. 23.
    Duhart BT Jr, Honaker MR, Shokouh-Amiri MH, Riely CA, Vera SR, Taylor SL, et al. Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation. Transpl Infect Dis. 2003;5(3):126–31.CrossRefGoogle Scholar
  24. 24.
    Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol. 2005;16(6):1758–74.CrossRefGoogle Scholar
  25. 25.
    Davies SE, Portmann BC, O'Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology. 1991;13(1):150–7.CrossRefGoogle Scholar
  26. 26.
    Di Bisceglie AM, Lok AS, Martin P, et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015;61(2):703–11.CrossRefGoogle Scholar
  27. 27.
    • Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83 American guidelines for diagnosis and management of HBV infection in the general population and special populations.CrossRefGoogle Scholar
  28. 28.
    Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606–15.CrossRefGoogle Scholar
  29. 29.
    Milburn J, Jones R, Levy JB. Renal effects of novel antiretroviral drugs. Nephrol Dial Transplant. 2017;32(3):434–9.PubMedGoogle Scholar
  30. 30.
    Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221–244 e223.CrossRefGoogle Scholar
  31. 31.
    Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, et al. The risk of transmission of hepatitis B from HBsAg(−), HBcAb(+), HBIgM(−) organ donors. Transplantation. 1995;59(2):230–4.CrossRefGoogle Scholar
  32. 32.
    Fabrizio F, Bunnapradist S, Martin P. Transplanting kidneys from donors with prior hepatitis B infection: one response to the organ shortage. J Nephrol. 2002;15(6):605–13.PubMedGoogle Scholar
  33. 33.
    Fong TL, Bunnapradist S, Jordan SC, Cho YW. Impact of hepatitis B core antibody status on outcomes of cadaveric renal transplantation: analysis of united network of organ sharing database between 1994 and 1999. Transplantation. 2002;73(1):85–9.CrossRefGoogle Scholar
  34. 34.
    Pilmore HL, Gane EJ. Hepatitis B-positive donors in renal transplantation: increasing the deceased donor pool. Transplantation. 2012;94(3):205–10.CrossRefGoogle Scholar
  35. 35.
    Veroux M, Corona D, Ekser B, Giaquinta A, Tallarita T, de Martino C, et al. Kidney transplantation from hepatitis B virus core antibody-positive donors: prophylaxis with hepatitis B immunoglobulin. Transplant Proc. 2011;43(4):967–70.CrossRefGoogle Scholar
  36. 36.
    • Huprikar S, Danziger-Isakov L, Ahn J, et al. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. Am J Transplant. 2015;15(5):1162–72 Consensus guidelines summarizing current evidence-based management of solid-organ transplant recipients of grafts (including renal) from HBV-positive donors.CrossRefGoogle Scholar
  37. 37.
    Veroux M, Puliatti C, Macarone M, Cappello D, Gagliano M, Spataro M, et al. Kidney transplantation from hepatitis B surface antigen-positive donors into hepatitis B surface antigen-positive recipients: preliminary findings. Transplant Proc. 2005;37(6):2467–8.CrossRefGoogle Scholar
  38. 38.
    Stock PG. A source of treatment for those who were (almost) lost: human immunodeficiency virus-positive to human immunodeficiency virus-positive kidney transplantation-results at 3 to 5 years. Transplantation. 2015;99(9):1744–5.CrossRefGoogle Scholar
  39. 39.
    Jiang H, Wu J, Zhang X, Wu D, Huang H, He Q, et al. Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: a prospective nonrandomized controlled study from a single center. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2009;9(8):1853–8.CrossRefGoogle Scholar
  40. 40.
    Singh G, Hsia-Lin A, Skiest D, Germain M, O'Shea M, Braden G. Successful kidney transplantation from a hepatitis B surface antigen-positive donor to an antigen-negative recipient using a novel vaccination regimen. Am J Kidney Dis. 2013;61(4):608–11.CrossRefGoogle Scholar
  41. 41.
    • Chancharoenthana W, Townamchai N, Pongpirul K, et al. The outcomes of kidney transplantation in hepatitis B surface antigen (HBsAg)-negative recipients receiving graft from HBsAg-positive donors: a retrospective, propensity score-matched study. Am J Transplant. 2014;14(12):2814–20 Retrospective study showing good outcomes and no HBV transmision following renal transplantation of renal grafts from HBsAg-positive donors without viremia into HBsAg-negative reciepients with documented immunity (anti-HBs).CrossRefGoogle Scholar
  42. 42.
    Tuncer M, Tekin S, Yucetin L, et al. Hepatitis B surface antigen positivity is not a contraindication for living kidney donation. Transplant Proc. 2012;44(6):1628–9.CrossRefGoogle Scholar
  43. 43.
    Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine. 2005;84(5):313–22.CrossRefGoogle Scholar
  44. 44.
    Zhang Y, Zhou JH, Yin XL, et al. Treatment of hepatitis B virus-associated glomerulonephritis: a meta-analysis. World J Gastroenterol. 2010;16(6):770–7.CrossRefGoogle Scholar
  45. 45.
    Wang WN, Wu MY, Ma FZ, et al. Meta-analysis of the efficacy and safety of nucleotide/nucleoside analog monotherapy for hepatitis B virus-associated glomerulonephritis. Clin Nephrol. 2016;85(1):21–9.CrossRefGoogle Scholar
  46. 46.
    Fabrizi F, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis. Aliment Pharmacol Ther. 2006;24(5):781–8.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Gastroenterology and HepatologyUniversity of Miami Miller School of MedicineMiamiUSA
  2. 2.University of Miami Miller School of MedicineMiamiUSA

Personalised recommendations